Eli Lilly said on June 7, 2026 that women with obesity or overweight who took the highest dose of Foundayo lost significant weight at every stage of menopause, based on post-hoc analyses from two late-stage trials. The company presented the findings at the American Diabetes Association's 86th Scientific Sessions.
The results drew attention because they add a large data set to a question that has often been left on the edge of obesity research: whether menopausal status changes how well a treatment works. The analyses covered more than 1,500 female participants in ATTAIN-1 and ATTAIN-2, including women with and without type 2 diabetes, and the outcomes were measured after 72 weeks.
In ATTAIN-1, women who were pre-menopausal lost up to 28.0 lbs, or 12.8%, on the highest dose of Foundayo. Peri-menopausal women lost up to 30.4 lbs, or 14.4%, while post-menopausal women lost up to 28.2 lbs, or 14.1%. In ATTAIN-2, which enrolled women with type 2 diabetes, pre-menopausal women lost up to 23.4 lbs, or 11.3%, peri-menopausal women lost up to 18.5 lbs, or 8.9%, and post-menopausal women lost up to 27.8 lbs, or 13.6%.
Rachel Batterham said menopause can be an incredibly frustrating time for many women because weight gain can feel beyond their control, and the biology of menopause can undermine even the most determined efforts to manage weight. She said the findings show Foundayo was associated with meaningful weight loss in women at every stage of menopause.
The waist measurements moved too. Women in ATTAIN-1 had reductions of up to 4.9 inches, or 12.5 cm, at 72 weeks, and women in ATTAIN-2 had reductions of up to 4.3 inches, or 11.0 cm. Lilly also said up to 51.5% of women in ATTAIN-1 and up to 44.2% in ATTAIN-2 reached at least 15% weight loss on the highest dose.
That matters because menopause is a major driver of weight gain, yet menopausal status has rarely been evaluated as a factor in obesity treatment efficacy. Batterham said that for women whose weight becomes harder to manage when their health is already more at risk, the results are what progress could look like.
What the company did not say is just as important as what it did: the announcement did not spell out whether these post-hoc findings will change Foundayo's regulatory path, its labeling or how it is prescribed. For now, the June 7 presentation makes the clearest case yet that the drug's effect on weight loss did not depend on where women were in menopause, and that could become the next point regulators and doctors focus on.
